Prognostic significance of CCL 20 and its receptor CCR 6 in cancers : a meta-analysis

Content Provider	Semantic Scholar
Author	Li, Yunhai Huang, Jing Tie, Hongtao Huang, Hongyan Li, Hongzhong Ren, Guosheng
Copyright Year	2016
Abstract	Growing evidence from recent publications has shown the association of CC chemokine ligand 20 (CCL20) and CC chemokine receptor 6 (CCR6) with outcomes of cancer, but the results remained controversial. The present meta-analysis was performed to investigate the prognostic value of CCL20 and CCR6 in cancer patients. PubMed and Embase were systematically searched to identify eligible studies. Two investigators independently performed study selection, data extraction and quality assessment. Hazard ratio (HR) and 95% confidence interval (CI) regarding overall survival (OS), disease-free survival (DFS) and relapse-free survival (RFS) were extracted and utilized to calculate pooled effect size. A total of 18 cohort studies with 2429 participants were included. High expression of CCL20 was demonstrated to associate with worse OS (HR = 2.38, 95% CI: 1.94-2.92, P < 0.001), DFS (HR = 2.16, 95% CI: 2.01-2.32, P < 0.001) and RFS (HR = 2.29, 95% CI: 1.58-3.33, P < 0.001) by fixed-effect model. Elevated CCR6 predicted poor OS (HR = 1.50, 95% CI: 1.02-2.20, P = 0.040) but not DFS (HR = 1.41, 95% CI: 0.56-3.53, P = 0.460) by random-effects model. Moreover, subgroup and sensitivity analyses for OS studies suggested that the results of CCL20 were robust, but caution should be taken for CCR6 analysis because of potential heterogeneity. This meta-analysis suggests that high expression of CCL20 and CCR6 predict poor prognosis in patients with carcinomas. Nevertheless, more well-designed and powerful cohort studies are required to further verify these conclusions.
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://www.ijcem.com/files/ijcem0018559.pdf
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article